Senescence Research in APPA with INIBIC

AKLRD has agreed a further collaboration with the Institute of Biomedical Research of A Coruña (INIBIC) to advance the understanding of APPA’s mechanism of action.  INIBIC is Spain’s leading biomedical research institution. Previous research at INIBIC has shown that APPA has a significant effect on senescent cells in human chondrocytes1 – see BMJ abstract. This […]

Read More

Completion of Phase 2a Human Trial

AKL Research and Development (AKLRD) has recently completed a Phase 2a, 28-day 150 patient, trial of oral APPA in osteoarthritis (OA) of the knee The data from this Phase 2a trial adds considerably to our understanding of APPA. It advances our ability to select the patients most likely to benefit from APPA. Key Findings from […]

Read More

MHRA awards Innovation Passport for APPA in Osteoarthritis

Following consideration by MHRA, NICE, and SMC, the Innovative Licensing and Access Pathway Steering Group has informed AKL Research & Development Ltd that the innovative medicine designation, the Innovation Passport, has been awarded for APPA in the treatment of osteoarthritis. The Innovation Passport is the entry point to the Innovative Licensing and Access Pathway (ILAP) […]

Read More

APPA reduces senescence & reactive oxygen species production

New data presented at the European League against Rheumatism (EULAR) demonstrates that APPA reduces the number of senescent chondrocytes, and inhibits ROS production in human articular chondrocytes. Today AKL Research & Development unveils new data at the Virtual European Congress of Rheumatology (EULAR) 2021 (June 2-5). Findings from the study indicate our investigational oral osteoarthritis […]

Read More

New studies suggests APPA protects against joint damage

Today sees the unveiling of new data at the Osteoarthritis Research Society International (OARSI) Virtual World Congress (April 29 – May 1) indicating investigational oral osteoarthritis (OA) drug APPA can modulate cellular function, reduce inflammation and inhibit bone resorption associated with joint degradation caused by the disease. Read full press release. Characterizing the effect of […]

Read More

APPA Phase II human study completes ahead of schedule

Despite Covid, the Phase II 150-patient placebo-controlled Human Efficacy Study of APPA in osteoarthritis of the knee has completed patient recruitment a month ahead of schedule and the last patient to enter the study completed their treatment on 16th April.

Read More